Temasek, cor­po­rate VCs buy in­to pre­scrip­tion dig­i­tal med hopes in Ak­il­i's $55M Se­ries C

Just how hot is “pre­scrip­tion dig­i­tal med­i­cine” these days? Ask the in­vestors back­ing Ak­ili In­ter­ac­tive, who col­lec­tive­ly sank $55 mil­lion in a Se­ries C an­nounced this morn­ing.

Boston-based Ak­ili, a PureTech af­fil­i­ate, is de­vel­op­ing a late-stage video game for pe­di­atric at­ten­tion deficit/hy­per­ac­tiv­i­ty dis­or­der (AD­HD) along­side oth­er soft­ware pro­grams in autism, de­pres­sion and mul­ti­ple scle­ro­sis. Temasek led the lat­est round, with par­tic­i­pa­tion from cor­po­rate VCs like Am­gen Ven­tures and M Ven­tures (of Mer­ck KGaA) as well as Jazz Ven­ture Part­ners, Bail­lie Gif­ford and Canepa Ad­vanced Health­care Fund — a group that co-founder and CEO Ed­die Mar­tuc­ci de­scribes as bring­ing “suc­cess­ful long-term track records in in­no­v­a­tive tech­nol­o­gy, med­ical de­vice and phar­ma­ceu­ti­cal in­vest­ment.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN